In the previous issue of *Critical Care*, we read with interest the article by Blankman and colleagues \[[@CR1]\], who studied the performance of various electrical impedance tomography (EIT)-derived measures in detecting the 'best' positive end-expiratory pressure. The aim of that study is relevant; however, the article contains some methodological inaccuracies that need to be clarified.

One of the EIT measures used to characterize ventilation distribution is the center of ventilation (COV), first introduced in \[[@CR2]\]. The authors refer appropriately to an article that contains a methodological figure illustrating how COV is derived from EIT ventilation images \[[@CR3]\]. However, the authors incorrectly state that COV is the ratio between the EIT-derived ventilations in the dorsal and whole-image regions, provide a wrong equation 6, and attribute it to \[[@CR3]\].

It is important for the understanding of EIT findings to appreciate that Figure one \[[@CR1]\] does not show images of 'impedance' and the degree of 'aeration' (legend) but of tidal impedance differences representing regional tidal volumes. Regional ventilation delay (RVD) was analyzed not in \[[@CR4]\], but in \[[@CR5]\], where it was calculated in each pixel. A two-dimensional map was produced from these values, and standard deviation was calculated as an aggregate measure of ventilation homogeneity. Equation 3 regarding RVD calculation was used in \[[@CR5]\], not in \[[@CR6]\], where an additional multiplication by maximum impedance amplitude of the studied low-flow inflation was included. It is not clear which percentages of regional compliance are presented in Figure two B \[[@CR1]\].

EIT is currently at an important stage of its development. Its clinical use might be fostered by implementation of accurate analysis tools.

COV

:   Center of ventilation

EIT

:   Electrical impedance tomography

RVD

:   Regional ventilation delay

See related research by Blankman *et al*. http://ccforum.com/content/18/3/R95
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